Semaglutides
Overview
Originally designed to treat diabetes, semaglutide has garnered significant attention in recent years for its use in weight loss treatments. The drug mimics a hormone naturally produced in the gut after meals and can trigger a number of similar responses that effectively trick the body into thinking it is full.
The drug is sold under the trade names Ozempic (injection) and Rybelsus (oral) for diabetes, and Wegovy (injection) for weight loss. As of spring 2026, two GLP-1 pill options were also available for weight loss—a Wegovy option and Eli Lilly's Foundayo.
Semaglutide is in a class of drugs called GLP-1 agonists, which mimic the hormone GLP-1. Humans produce GLP-1 when they eat, and the hormone causes the body to produce insulin—hence its use to treat diabetes. However, GLP-1 also activates receptors in the nervous system, the stomach, and the gut. Each receptor triggers a different response, including slowing the passage of food through the digestive system and prompting the brain to send signals of fullness.
1440 Findings
Hours of research by our editors, distilled into minutes of clarity.
Explore Health & Medicine
Indulge your curiosity, from the inner workings of our bodies and minds to the latest in medical research and treatments, all aimed at enhancing your understanding of health, wellness, and medicine. Our resources are meticulously curated to offer precise and pertinent information to anyone interested in learning more about the medical sciences.

